
Eli Lilly (LLY) Stock Forecast & Price Target
Eli Lilly (LLY) Analyst Ratings
Bulls say
Eli Lilly is well-positioned for growth, with a diverse portfolio of drugs targeting key healthcare areas such as neuroscience, cardiometabolic, cancer, and immunology. The positive projected revenue and EPS, along with the company's CEO's goal for double-digit growth and expansion into new markets, further solidify its strong potential for success. Despite potential risks and competition, Eli Lilly's strong emphasis on innovation and acquisition strategy make it a promising stock for the future.
Bears say
Eli Lilly is experiencing a decline in their EP business, leading to a decrease in sales and earnings. Although they have multiple growth catalysts and a strong position in the MedTech industry, their stock performance is dependent on upcoming trial results and investor sentiment. There are also risks to the company's rating and price target, including potential competition, failed R&D efforts, and external factors such as supply chain disruptions and geopolitical issues. Overall, the negative outlook stems from the current decline in EP revenue and uncertainties surrounding future performance and external risks.
This aggregate rating is based on analysts' research of Eli Lilly and is not a guaranteed prediction by Public.com or investment advice.
Eli Lilly (LLY) Analyst Forecast & Price Prediction
Start investing in Eli Lilly (LLY)
Order type
Buy in
Order amount
Est. shares
0 shares